November 09, 2015 (Shareholders Foundation) - An investigation on behalf of investors of Dr.Reddys Laboratories Ltd (ADR) (NYSE:RDY) shares over potential securities laws violations by Dr.Reddys Laboratories Ltd and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Dr.Reddys Laboratories Ltd (ADR) (NYSE:RDY) concerning whether a series of statements by Dr.Reddys Laboratories Ltd regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Dr.Reddy's Laboratories Ltd reported that its Total Revenue rose from over $1.46 billion for the 12 months period that ended on March 31, 2012 to over $2.24 billion for the 12 months period that ended on March 31, 2015 and that its Net Income for those respective time periods increased from $215.87 million to $335.69 million.

Shares of Dr.Reddy's Laboratories Ltd (ADR) (NYSE:RDY) grew from $27.71 per share in June 2012 t as high as $68.00 per share on October 19, 2015.

On November 6, 2015, Dr.Reddy's Laboratories Ltd (ADR) (NYSE:RDY) issued a statement acknowledging that it has received a warning letter issued by the US FDA dated November 05, 2015 relating to its API manufacturing facilities at Srikakulam, Andhra Pradesh and Miryalaguda, Telangana, as well as Oncology Formulation manufacturing facility at Duvvada, Visakhapatnam, Andhra Pradesh. Dr.Reddy's Laboratories Ltd said that this action follows the earlier inspections of these sites by the agency in November 2014, January 2015 and February 2015 respectively.